GSK's swine flu vaccine launched

Pandemrix is one of two vaccines now available for swine flu prophylaxis in high-risk patients.

Pandemrix should be used in accordance with official guidance.

The dose recommendations are based on safety and immunogenicity data available from the administration of AS03-adjuvanted vaccine containing 3.75 microgram HA derived from A/Vietnam/1194/2004 (H5N1) in adults including the elderly. Half the dose was given to children 3-9 years old and doses were given on days 0 and 21.

Limited immunogenicity data suggest that a second dose may not be required in healthy adults aged 18-60 years.

View Pandemrix drug record

Further information: GSK

To sign up for the MIMS monthly news update, register at

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more